Clinical Trial: A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07823829) titled 'A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma' on Sept. 08.

Brief Summary: This is a single-arm, open-label, dose-finding Phase I/II clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics, and pharmacodynamics of CT1190B cells in patients with R/R LBCL.

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Large B-Cell Lymphoma (LBCL)

Intervention: DRUG: CT1190B intravenous infusion

68 subjects received 1190B injection for infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: UCARsgen Biotech Limited

Published by HT Digital Content Services with p...